Kemik Metastazı Bulunan Hastalara Multidisipliner Yaklaşım

Öz

İskelet sistemi en sık şiddetli ağrılara yol açan metastaz lokalizasyon bölgesidir. İleri dönem kanser hastalarında, kemoterapi, analjezikler, hormon tedavisi gibi tedavi yöntemleri yetersiz kalabilmektedir. Kemik ağrılarının palyasyonunda radyoterapi etkin bir tedavidir. Kemik metastazlarında radyoterapinin amacı; ağrıyı azaltmak, patolojik fraktür gelişmesini önlemek, morbiditeyi azaltırken fonksiyonu iyileştirmek ve yaşam kalitesini yükseltmektir. Kemikte tutulan Sr-89 Strontiumchloride, Sm-153 Samariumlexidronam ve Re-186 Rheniumetidronate gibi radyofarmasötiklerde ağrı palyasyonundayeni bir tedavi seçeneği olup, yaygın kemik metastazı olan hastalarda etkinliği gösterilmiştir. Radyonüklid tedavi ağrının azaltılması, yaşam kalitesinin artırılması ve yeni ağrı odaklanılın gelişiminin azaltılmasında etkili bir yöntemdir.

Anahtar Kelimeler

• Kemik metastazı,Radyoterapi,Radyonüklid tedavi

Multidisciplinary Approach to Patients with Bone Metastasis

Öz

Bone metastases are very frequent causes of intractable pain in cancer patients. Since therapeutic methods that chemotherapy, analgesics, hormonal therapy may be insufficient in patients with advanced cancer disease.
Radiotherapy in the palliation of bone pain is an effective treatment. Purpose of radiotherapy in bone metastases; reducing pain, preventing pathological fractures, improving function and improving quality of life while reducing morbidity. Bone seeking radiopharmaceuticals that Sr-89 Strontiumchloride, Sm-153 Samariumlexidronam and Re-186 Rheniumetidronate have provided a new option to these management strategies and have been proven to be effective in patients with widespread bone metastases. Radionuclide therapy is an effective method in the reduction of bone pain, in the enhancement of life quality and in preventing the development of new painful metastatic sites.

Anahtar Kelimeler

• Bone metastasis,Radiotherapy,Radyonuclide therapy

Kaynakça

1. 1. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence an and future directions. Cancer Treat Rev. 2008;34(7):629-39.
2. 2. Paller CJ, Carducci MA, Philips GK. Management of bone metastases in refractory prostate cancer-role of denosumab. Clin Interv Aging. 2012;7:363-372.
3. 3. Costantini M, Ripamonti C, Beccaro M, Montella M, Borgia P, Casella C, et al. Prevalence, distress, management, andrelief of painduringthelast 3 months of cancerpatients’ life. Results of an Italian mortality follow-back survey. Ann Oncol. 2009;20(4):729-735.
4. 4. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420-33.
5. 5. Ömür Ö, Kapulu C, Uğur Ö. Kas iskelet sistemi hastalıklarında nükleer tıp yöntemleri. TOTBİD Dergisi. 2007;6:1-29.
6. 6. 6)Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001;42(6):895-906.
7. 7. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353(9165):1695-700.
8. 8. Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153 Sm EDTMP in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.

9. 9. Taylor AJ. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med. 1994;35:2054.
10. 10. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. Final results of the study by Radiation Oncology Group. Cancer. 1982;50:893-899. Mc Ewan AJ, Porter AT, Venner PM, et al. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibod Immunoconj Radiopharm. 1990;3:91-98.
11. 11. Baczyk M. Radioisotope therapy of bone metastases. Nucl Med Rev Cent East Eur. 2011;14(2):96-104.
12. 12. McEwan AJB. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med. 1996;27:165-182.
13. 13. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451-1458.
14. 14. Serafini AN. Therapy of metastatic bone pain. J NuclMed 2001;42(6):895–906. Lewington VJ. Cancertherapyusing bone-seekingisotopes. Phys Med Biol. 1996;41:2027–2042.
15. 15. Guerra Liberal FDC, Tavares AAS, Joao Manuel RS. Tavares N. Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153. Appl Radiat Isot. 2016;110:87–99.
16. 16. Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl MedMol Imaging. 2008;35(4):756-65.
17. 17. Joensuu T, Joensuu G, Kairemo K, Kiljunen T, Riener M, Aaltonen A, et al. Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. Anticancer Res. 2016;36(12):6439-6447.
18. 18. Gul SS, Sonmez O, Deveci EK, Ilce HT, Ergonenc JS. Quantitative assessment of radionuclide pain palliation: case report. Türk Onkoloji Dergisi. 2013;28(2):75-80.
19. 19. Heron DE, Brufsky A, Beriwal S, Kurman M. Myelotoxicity of samariumSm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Ann Oncol. 2008;19(9):1639-1643.
20. 20. Porter AT, Mc Ewan AJ, Powe JE, et al. Results of a randomized phase-III trialtoevaluatetheefficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
21. 21. EANM Procedure Guidelines for Treatment of Refractory Metastatic Bone Pain. Eur J Nucl Med. 2003;30:7-11.
22. 22. McEwan AJB. Palliation of bone pain. In: Ell PJ, Gambhir SS. Nuclear Medicine in Clinical Diagnosis and Treatment, vol 1. elsevier Limited, Philadelphia. 2004, pp 407-422.
23. 23. Blitzer P H. Reanalysis of the RTOG study of the palliation of symtomatic osseous metastases. Cancer. 1985;55:1468-1472.
24. 24. Hoskin PJ, Stratford MRL, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355:1428-1429.
25. 25. Güney Y, Yılmaz S, Özel Türkcü Ü, Kurtman C. Kemik metastazlarında tanı ve tedavi. Acta Oncologica Turcica. 2008;41:1-6.
26. 26. Chisholm G D, Rana A, Howard G C W. Management options for painful carcinoma of the prostat. Seminars in Oncology. 1993;20:34-37.
27. 27. 25)Martin MM, Thomas DF. Treatmant of metastatic cancer of bone. In: De Vita V T, Helman S, Rosenberg SA, Eds. Cancer, Principles and Practice of Oncology, Philadelphia: J.B. Lippincott Company. 1993:2225-22.
28. 28. Price P, Hoskin PJ, Easton D. A prospective randomised trial of 4 Gyor 8 Gysingle doses in the treatment of metastatic bone pain. Radiotherapy and Oncology. 1992;23:74-78.